When was Okomera founded?

Okomera was founded in 2020 and raised its 1st funding round 3 years after it was founded.

Where is Okomera located?

Okomera is headquartered in Paris, France.

Who is the current CEO of Okomera?

Aimee Wessel of Okomera. They have also founded 1 company.

How many employees does Okomera have?

As of Aug 31, 2026, the latest employee count at Okomera is 24.

Is Okomera a funded company?

Okomera is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Dec 20, 2023.

When was the latest funding round of Okomera?

Okomera's latest funding was a $***** Seed round on Dec 20, 2023, with participation from 4 investors.

Where does Okomera rank among its competitors?

Okomera ranks 8th amongst 49 active competitors, of which 21 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Emulate, which secured $493K in Sep, 2025.

Who are the top competitors of Okomera?

Okomera's top competitors include Mimetas, Emulate and CN Bio. Among them, Emulate secured the most recent funding round in September, 2025.

Okomera - 2026 Company Profile, Team, Funding & Competitors

Okomera is a seed company based in Paris (France), founded in 2020 by Aimee Wessel, Charles Baroud and Raphael Tomasi. It operates as a Developer of a device for in vitro cancer testing using a microfluidic chip. Okomera has raised $11.2M in funding from investors like Berkeley SkyDeck Fund, Polytechnique Ventures and Resonance. The company has 49 active competitors, including 21 funded and 2 that have exited. Its top competitors include companies like Mimetas, Emulate and CN Bio.

Company Details

Developer of a device for in vitro cancer testing using a microfluidic chip. The company's proprietary technology can be used for personalised treatment and testing of cancer cells in 3D spheroids. It is used for the study of tumour biopsy.

Key Metrics

Founded Year

2020

Location

Paris, France

Stage

Seed

Total Funding

$11.2M in 1 round

Latest Funding Round

Seed, Dec 20, 2023, $*****

Investors

Berkeley SkyDeck Fund & 5 more

Ranked

8^th among 49 active competitors

Employee Count

24 as on Aug 31, 2026

Investment & Acquisitions

NEOGAP

Similar Companies

Mimetas & 50 more

View Okomera's full profile

Okomera has raised a total funding of $11.2M over 1 round. Its latest funding round was a Seed round on Dec 20, 2023 for $*****. 4 investors participated in its latest round. Okomera has 6 institutional investors.

Here is the list of recent funding rounds of Okomera:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 20, 2023	8662876	Seed	2925127	9014610	8318236	2804065

Access funding benchmarks and valuations. Sign up today!

View details of Okomera's funding rounds and investors

The founders of Okomera are Aimee Wessel, Charles Baroud and Raphael Tomasi. Aimee Wessel is the CEO of Okomera.

Here are the details of Okomera's key team members:

Aimee Wessel: Co-Founder & CEO of Okomera.
Charles Baroud: Co-Founder of Okomera.
Raphael Tomasi: Co-Founder of Okomera.

View details of Okomera's Founder profiles and Board Members

Okomera's employee count trend

Okomera has 24 employees as of Aug 26. Here is Okomera's employee count trend over the years:

Uncover Okomera's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Okomera include Mimetas, Emulate and CN Bio. Here is the list of Top 10 competitors of Okomera, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Mimetas 2013, Leiden (Netherlands), Acquired	Develops microfluidics-based organ-on-a-chip tissue models	$28.9M	Zeeuws Investerings Fonds, Oost NL & 13 others	60/100
2nd	Emulate 2013, Boston (United States), Series E	Developer of in vitro models for drug development	$204M	ND Capital, Cedars Sinai & 25 others	58/100
3rd	CN Bio 2009, Cambridge (United Kingdom), Series B	Develops organ-on-a-chip platforms for drug discovery	$71.2M	CITIC, Zray Management & 13 others	58/100
4th	Vivodyne 2021, Philadelphia (United States), Series A	Developer of AI-based platform for lab-grown human tissues	$80M	Khosla Ventures, MBX Capital & 6 others	55/100
5th	Hesperos 2015, Orlando (United States), Funding Raised	Developer of organ-on-a-chip solutions for preclinical testing	-	HHS, NCATS	53/100
6th	Obatala Sciences 2017, New Orleans (United States), Series A	Provider of research enabling products and services to research centers	$3.54M	Ochsner, être & 9 others	44/100
7th	Numa Biosciences 2007, Woodinville (United States), Acquired	Developer of platform for generating small segments of human tissues and organs in microfluidic chips	$10.7M	SeaChange Fund, Vertical Venture Partners ... & 3 others	43/100
8th	Okomera 2020, Paris (France), Seed	Developer of a device for in vitro cancer testing using a microfluidic chip	$11.2M	Otium Capital, Village Capital & 4 others	42/100
9th	AxoSim 2014, New Orleans (United States), Series A	Engineering human brain and nerve models for neurological insights	$6.78M	Benson Capital Partners, Great Stuff Ventures ... & 9 others	40/100
10th	NETRI 2018, Lyon (France), Series A	Developer of microfluidic devices for industrial applications	$14M	Bpifrance, Netangels & 4 others	40/100